Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathryn L Chapman

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Human Mutation|April 23, 2002
Pseudoachondroplasia and multiple epiphyseal dysplasia: mutation review, molecular interactions, and genotype to phenotype correlationsMichael D Briggs, Kathryn L Chapman
Biochimica Et Biophysica Acta|October 24, 2012
The melanocortin 4 receptor: oligomer formation, interaction sites and functional significanceKathryn L Chapman, John B C Findlay
Pediatric Pathology & Molecular Medicine|April 12, 2003
Review: clinical variability and genetic heterogeneity in multiple epiphyseal dysplasiaKathryn L Chapman, Michael D Briggs, Geert R Mortier
Drug Discovery Today|January 26, 2010
The future of non-human primate use in mAb developmentKathryn L Chapman, Nick Pullen, Laura Andrews, et al.
Preventing Chronic Disease|September 17, 2009
Hospice use among cancer decedents in Alabama, 2002-2005Todd M Jenkins, Kathryn L Chapman, Dorothy S Harshbarger, et al.
Journal of Cellular and Molecular Medicine|August 29, 2020
IKKε and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKε/TBK1 inhibitor to repress NF-κB and IL-10 signallingMatthew Carr, Sami Mamand, Kathryn L Chapman, et al.
Drug Discovery Today|August 25, 2020
Releasing the technical 'shackles' on GPCR drug discovery: opportunities enabled by detergent-free polymer lipid particle (PoLiPa) purificationJ Daniel Hothersall, Andrew Y Jones, Tim R Dafforn, et al.
Journal of Molecular Biology|July 6, 2010
Interactions of the melanocortin-4 receptor with the peptide agonist NDP-MSHKathryn L Chapman, Gemma K Kinsella, Alan Cox, et al.
European Journal of Pharmacology|December 1, 2010
The muscarinic M(4) receptor is the functionally predominant subtype in rat and mouse striatum as demonstrated using [(35)S] GTPγS bindingKathryn L Chapman, Dina Vaswani, Nicola Hendry, et al.
Journal of Pain and Symptom Management|January 18, 2011
Hospice use in Alabama, 2002-2005Todd M Jenkins, Kathryn L Chapman, Christine S Ritchie, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Human Mutation|April 23, 2002
Pseudoachondroplasia and multiple epiphyseal dysplasia: mutation review, molecular interactions, and genotype to phenotype correlationsMichael D Briggs, Kathryn L Chapman
Biochimica Et Biophysica Acta|October 24, 2012
The melanocortin 4 receptor: oligomer formation, interaction sites and functional significanceKathryn L Chapman, John B C Findlay
Pediatric Pathology & Molecular Medicine|April 12, 2003
Review: clinical variability and genetic heterogeneity in multiple epiphyseal dysplasiaKathryn L Chapman, Michael D Briggs, Geert R Mortier
Drug Discovery Today|January 26, 2010
The future of non-human primate use in mAb developmentKathryn L Chapman, Nick Pullen, Laura Andrews, et al.
Preventing Chronic Disease|September 17, 2009
Hospice use among cancer decedents in Alabama, 2002-2005Todd M Jenkins, Kathryn L Chapman, Dorothy S Harshbarger, et al.
Journal of Cellular and Molecular Medicine|August 29, 2020
IKKε and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKε/TBK1 inhibitor to repress NF-κB and IL-10 signallingMatthew Carr, Sami Mamand, Kathryn L Chapman, et al.
Drug Discovery Today|August 25, 2020
Releasing the technical 'shackles' on GPCR drug discovery: opportunities enabled by detergent-free polymer lipid particle (PoLiPa) purificationJ Daniel Hothersall, Andrew Y Jones, Tim R Dafforn, et al.
Journal of Molecular Biology|July 6, 2010
Interactions of the melanocortin-4 receptor with the peptide agonist NDP-MSHKathryn L Chapman, Gemma K Kinsella, Alan Cox, et al.
European Journal of Pharmacology|December 1, 2010
The muscarinic M(4) receptor is the functionally predominant subtype in rat and mouse striatum as demonstrated using [(35)S] GTPγS bindingKathryn L Chapman, Dina Vaswani, Nicola Hendry, et al.
Journal of Pain and Symptom Management|January 18, 2011
Hospice use in Alabama, 2002-2005Todd M Jenkins, Kathryn L Chapman, Christine S Ritchie, et al.
Pageof 2